Biotech - Technical Analysis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (314)	4/9/2002 11:02:00 PM
From: Jibacoa	Read Replies (1) of 544

HEPH moved up from the 6 support level today.<g> siliconinvestor.com It still has to close above the March 13 H at 7.74 before trying for the more heavier resistance at the 9.50 to 9.75 levels ( from the February 14 H and the late January Ls).<g> siliconinvestor.com And HEPH has still further resistance hurdles before trying to test the January 14 H at 12.24 or the December 10 H at 14.25.<g> siliconinvestor.com But as I mentioned the support at the 6 level looks pretty good and it seems with some help it could make it to the 10 level for a 50% gain.<g> siliconinvestor.com HEPH has several products in its pipeline.<g> Its lead drug is HE2000, which is currently being studied in clinical trials for HIV/AIDS in South Africa, and also on a Phase II in the U.S. That same drug is being tested in a Phase II in Thailand for the treatment of malaria, and in Singapore for the treatment of hepatitis B. Its HE2500 is currently on a Phase II trial for cardiovascular disease and has shown some activity in other indications. HE2100 is as a radioprotectant to be jointly developed with the U.S. military. Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next